The Oncotype DX GPS test is a prostate cancer diagnosis and treatment service designed for men with low, intermediate and high risk localized prostate cancer. It examines prostate cancer gene activity to predict disease aggressiveness and help guide treatment decisions during diagnosis. Precision diagnostics company MDxHealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences for up to $100 million.
This article is reprinted from: https://www.itjuzi.com/merger/9189
This site is for inclusion only, and the copyright belongs to the original author.